Summary
Unable to audit the AI claims against the provided FDA label excerpt because the excerpt pertains to ERIVEDGE (vismodegib) for basal cell carcinoma and does not include the KRAS G12C NSCLC indication, dosing, contraindications, warnings/precautions, drug interactions, or other critical label sections needed to verify the supplied claims.
Category Scores
Accurate Statements
Erivedge is an inhibitor of the Hedgehog pathway (Hh pathway inhibitor).
12.1 Mechanism of Action (vismodegib is an inhibitor of the Hedgehog pathway; binds/inhibits Smoothened).
Unsupported Statements
Erivedge (sotorasib) is a small-molecule inhibitor.
The provided label excerpt for ERIVEDGE describes vismodegib (Hedgehog pathway inhibitor) for basal cell carcinoma and does not mention sotorasib.
Erivedge (sotorasib) is approved for KRAS G12C–mutant non-small-cell lung cancer.
The provided label excerpt indicates ERIVEDGE for metastatic or locally advanced basal cell carcinoma; no KRAS G12C NSCLC indication is present.
Erivedge was developed by Amgen.
The provided label excerpt does not state developer/manufacturer or company development attribution.
Erivedge patents are owned by Amgen.
The provided label excerpt contains no patent ownership information.
Some rights to Erivedge patents are licensed to other companies for specific territories.
The provided label excerpt contains no patent licensing/territory information.
Erivedge core patents cover the compound itself.
The provided label excerpt contains no patent scope details.
Erivedge core patents cover formulation.
The provided label excerpt contains no patent scope details.
Erivedge core patents cover method of use for KRAS-driven cancers.
The provided label excerpt contains no patent scope details, and the label indication provided is basal cell carcinoma rather than KRAS-driven cancers.
Amgen’s portfolio includes composition-of-matter patents for sotorasib and its salt forms.
The provided label excerpt is for ERIVEDGE (vismodegib) and does not mention sotorasib or patents.
Amgen’s portfolio includes process patents for the synthesis route.
The provided label excerpt contains no patent/process information.
Amgen’s portfolio includes use patents that claim the treatment of KRAS G12C tumors.
The provided label excerpt contains no patent/use information and no KRAS G12C tumor indication.
The most robust Erivedge patents are filed in the United States.
The provided label excerpt contains no patent filing/jurisdiction information.
The most robust Erivedge patents are filed in the European Union.
The provided label excerpt contains no patent filing/jurisdiction information.
The most robust Erivedge patents are filed in other major markets.
The provided label excerpt contains no patent filing/jurisdiction information.
The earliest expiring composition patent in the United States is set to lapse in 2029.
The provided label excerpt contains no patent expiration dates.
The process patents run until 2031.
The provided label excerpt contains no patent expiration dates.
In the European Union, the patent expiration dates align closely.
The provided label excerpt contains no patent expiration information.
Amgen has roughly a decade of market exclusivity before generic competition can enter in the European Union.
The provided label excerpt contains no market exclusivity/generic entry timeline information.
Generic entry is unlikely before the final patent expiration because patents covering the active ingredient and its therapeutic use remain in force.
The provided label excerpt contains no patent/legal status information or statements about generic entry likelihood.
Biosimilars are not applicable for a small-molecule drug like Erivedge.
The provided label excerpt contains no discussion of biosimilars.
The only route to competition is a generic that must wait until the relevant patents expire.
The provided label excerpt contains no discussion of competition pathways or patent-driven generic timelines.
Contradictions
High
AI Statement
Erivedge (sotorasib) is approved for KRAS G12C–mutant non-small-cell lung cancer.
Label Reference
1 INDICATIONS AND USAGE (ERIVEDGE is indicated for metastatic basal cell carcinoma or locally advanced basal cell carcinoma meeting specified criteria; no KRAS G12C NSCLC indication in provided label).
Medium
AI Statement
Erivedge (sotorasib) is a small-molecule inhibitor.
Label Reference
11 DESCRIPTION + 12.1 Mechanism of Action (provided label excerpt describes ERIVEDGE as vismodegib, a Hedgehog pathway inhibitor; the excerpt does not describe sotorasib).
Important Omissions
Verification of dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, and use in specific populations cannot be performed because the provided label excerpt does not include these sections and the AI claims provided are mostly non-label legal/patent assertions.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The AI claims include an incorrect indication (KRAS G12C NSCLC) for a drug labeled in the excerpt for basal cell carcinoma, which could lead to clinically unsafe misrepresentation relative to the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Incorrect mapping of ERIVEDGE to sotorasib and to an unrelated KRAS G12C NSCLC indication; multiple legal/patent exclusivity statements are not supported by the provided FDA label excerpt.
Suggested Improvement
Restrict statements to content present in the FDA-approved labeling excerpt (e.g., vismodegib/ERIVEDGE description and labeled basal cell carcinoma indication), and omit or separately source any patent/legal exclusivity assertions not contained in the label.